✦ LIBER ✦

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

✍ Scribed by Kowdley, Kris V; Lawitz, Eric; Crespo, Israel; Hassanein, Tarek; Davis, Mitchell N; DeMicco, Michael; Bernstein, David E; Afdhal, Nezam; Vierling, John M; Gordon, Stuart C; Anderson, Jane K; Hyland, Robert H; Dvory-Sobol, Hadas; An, Di; Hindes, Robert G; Albanis, Efsevia; Symonds, William T; Berrey, M Michelle; Nelson, David R; Jacobson, Ira M

Book ID: 121528808
Publisher: The Lancet
Year: 2013
Tongue: English
Weight: 241 KB
Volume: 381
Category: Article
ISSN: 0140-6736
DOI: 10.1016/S0140-6736(13)60247-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Sofosbuvir in combination with peginterf

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

✍ Lawitz, Eric; Lalezari, Jay P; Hassanein, Tarek; Kowdley, Kris V; Poordad, Fred 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 276 KB

Sofosbuvir and ledipasvir fixed-dose com

Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

✍ Lawitz, Eric; Poordad, Fred F; Pang, Phillip S; Hyland, Robert H; Ding, Xiao; Mo 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 400 KB

Efficacy of boceprevir, an NS3 protease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

✍ Paul Y Kwo; Eric J Lawitz; Jonathan McCone; Eugene R Schiff; John M Vierling; Da 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 378 KB

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial

✍ Jacobson, Ira M; Dore, Gregory J; Foster, Graham R; Fried, Michael W; Radu, Moni 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 284 KB

Simeprevir with pegylated interferon alf

Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial

✍ Manns, Michael; Marcellin, Patrick; Poordad, Fred; de Araujo, Evaldo Stanislau A 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 287 KB

Boceprevir versus placebo with pegylated

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

✍ Sulkowski, Mark; Pol, Stanislas; Mallolas, Josep; Fainboim, Hugo; Cooper, Curtis 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 333 KB